NCT06627868

Nicotinamide Adenine Dinucleotide (NAD+) Metabolism in Human Brown Adipose Tissue

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 68 (estimated)
• Sponsor: University of Turku · Academic / Other
• Sex: All
• Age: 30 Years – 65 Years
• Healthy volunteers: Accepted

Summary

A fully functional brown fat helps maintain a healthy weight and decreases the risk of metabolic diseases such as type II diabetes (T2DM). Unfortunately, in human adults, the functionality of brown fat declines with age, and it is one of the reasons for gaining unhealthy weight, particularly around the waistline (central obesity). Currently, scientists do not clearly understand the reasons for the decline in brown fat functionality. It is possible that the decline in the availability of the molecule Nicotinamide Adenine Dinucleotide (NAD+), which is central to several metabolic processes, plays a role in the decline in brown fat metabolism. This project will clarify whether NAD+-based molecular-targeted therapies for the enhancement of whole-body insulin sensitivity and brown fat metabolism will be successful in adult humans, which will eventually be an important target for reducing the development of obesity and its comorbidities such as T2DM.

Conditions

• Obesity, Abdominal

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	NAD+ precursor	NAD+ precursor supplementation (Nicotinamide, Nicotinamide Riboside, or Nicotinamide Mononucleotide)
OTHER	Placebo	Oral placebo daily intake for 6 months

Timeline

• Start date: 2024-11-20
• Primary completion: 2027-08-31
• Completion: 2027-08-31
• First posted: 2024-10-04
• Last updated: 2026-02-18

Locations

1 site across 1 country: Finland